ActualEyes Inc. announces the implementation of Series C financing by a domestic pharmaceutical company, bringing its accumulated fundraising to 850 million JPY. The Series C round is ongoing and expected to reach 1 billion JPY upon completion.
We are pleased to inform you that the first patient in our domestic Phase II clinical trial of AE101, a regenerative medicine cell product under development by ActualEyes Inc., has successfully received the transplantation. AE101 is designed for the treatment of bullous keratopathy (see Note 1). We are also pleased to report that the necessary safety evaluations have been completed, allowing for the continuation of the trial with subsequent patients.
We are honored to welcome the world-renowned ophthalmologist, Dr. Prema Padmanabhan, as an advisor to our company. Dr. Padmanabhan has been a leading figure in treating corneal diseases at Sankara Nethralaya, one of India’s premier eye hospitals, for many years. Sankara Nethralaya is one of the largest eye specialty hospitals globally, known for its cutting-edge treatments and research, attracting patients and specialists from across India and around the world.
Leveraging Dr. Padmanabhan’s extensive experience and exceptional expertise, our company aims to accelerate the development of treatments for corneal diseases. This collaboration will enable us to swiftly bring innovative therapies to market, significantly improving patients’ quality of life. With Dr. Padmanabhan’s invaluable guidance, we are poised to take our product development to new heights and achieve groundbreaking advancements in the field.
Professor Baratz serves as a distinguished professor of ophthalmology at the Mayo Clinic, one of the leading medical institutions in the United States. Specializing in corneal diseases, he has performed numerous ophthalmic surgeries, including corneal transplants. His groundbreaking research includes findings that the SNP in the TCF4 gene is associated with Fuchs corneal endothelial dystrophy, which accounts for approximately 40% of corneal transplantation cases in the world1. Furthermore, he discovered that a trinucleotide repeat sequence expansion in the TCF4 gene is present in about 80% of patients with the disease2, which has greatly influenced the understanding of the disease’s mechanism and the development of treatments.
Professor Baratz’s role as an advisor to our company is pivotal. His expertise and insights will be instrumental in the development of treatments for Fuchs’ endothelial dystrophy and products related to corneal endothelial regeneration.
ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA’s 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.
This website uses cookies for the purpose of operating our services and improving the user experience. For details, please refer to our privacy policy. By clicking on the “Agree” button or continuing to use our website, you will be regarded as having agreed to our use of cookies.